---
title: "Vertex Pharmaceuticals Incorporated (VRTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VRTX.US.md"
symbol: "VRTX.US"
name: "Vertex Pharmaceuticals Incorporated"
industry: "Biotechnology"
datetime: "2026-04-17T00:41:26.550Z"
locales:
  - [en](https://longbridge.com/en/quote/VRTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VRTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VRTX.US.md)
---

# Vertex Pharmaceuticals Incorporated (VRTX.US)

## Company Overview

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.vrtx.com](https://www.vrtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:18.000Z

**Overall: B (0.31)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.90% |  |
| Net Profit YoY | 838.09% |  |
| P/B Ratio | 6.02 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 112350694949.50 |  |
| Revenue | 12001300000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 22.54% | A |
| Profit Margin | 32.94% | A |
| Gross Margin | 53.67% | B |
| Revenue YoY | 8.90% | B |
| Net Profit YoY | 838.09% | A |
| Total Assets YoY | 13.80% | B |
| Net Assets YoY | 13.75% | B |
| Cash Flow Margin | 91.86% | C |
| OCF YoY | 8.90% | B |
| Turnover | 0.50 | C |
| Gearing Ratio | 27.21% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vertex Pharmaceuticals Incorporated",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.90%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "838.09%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.02",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "112350694949.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "12001300000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "22.54%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "32.94%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "53.67%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "8.90%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "838.09%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.80%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.75%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "91.86%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "8.90%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.21%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.42 | 48/393 | 31.46 | 29.63 | 27.91 |
| PB | 6.02 | 340/393 | 6.98 | 6.55 | 6.03 |
| PS (TTM) | 9.36 | 158/393 | 10.39 | 9.83 | 9.16 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-16T04:00:00.000Z

Total Analysts: **33**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 22 | 67% |
| Overweight | 5 | 15% |
| Hold | 4 | 12% |
| Underweight | 1 | 3% |
| Sell | 1 | 3% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 435.65 |
| Highest Target | 641.00 |
| Lowest Target | 330.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VRTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VRTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VRTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VRTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**